LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality
November 13 2017 - 7:30AM
Business Wire
Receives Designation as a Best Place to Work
for LGBTQ Equality
LabCorp (NYSE: LH), a leading global life sciences company,
announced that it received a perfect score of 100 percent on the
2018 Corporate Equality Index (CEI), a national benchmarking survey
and report on corporate policies and practices related to lesbian,
gay, bisexual, transgender and queer (LGBTQ) workplace equality,
administered by the Human Rights Campaign Foundation.
“We are pleased to receive this recognition,” said David P.
King, chairman and CEO of LabCorp. “At LabCorp, we seek to set an
unequivocal tone and standard of treating every person with dignity
and respect. The CEI recognition demonstrates that our 57,000
colleagues around the globe hold each other accountable to these
values and to a positive work environment and culture.”
The 2018 CEI rated 947 businesses in the report, which evaluates
LGBTQ-related policies and practices including non-discrimination
workplace protections, domestic partner benefits,
transgender-inclusive health care benefits, competency programs,
and public engagement with the LGBTQ community. LabCorp’s efforts
in satisfying all of the CEI’s criteria resulted in a 100 percent
ranking and the designation as a Best Place to Work for LGBTQ
Equality.
This is the first time LabCorp formally participated in the
survey, achieving the highest score on its initial submission.
About the Human Rights Campaign Foundation
The Human Rights Campaign Foundation is the educational arm of
America's largest civil rights organization working to achieve
equality for lesbian, gay, bisexual, transgender and queer people.
For more information on the 2018 Corporate Equality Index, or to
download a free copy of the report, visit www.hrc.org/cei.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
nearly $9.5 billion for 2016. To learn more about LabCorp, visit
www.labcorp.com, and to learn more about Covance Drug Development,
visit www.covance.com.
Forward-Looking Statements
This press release contains forward-looking statements including
with respect to estimated 2017 guidance and the impact of various
factors on operating and financial results. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive
actions in the marketplace, and adverse actions of governmental and
other third-party payers. Actual results could differ materially
from those suggested by these forward-looking statements. The
Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. Further
information on potential factors that could affect operating and
financial results is included in the Company’s Form 10-K for the
year ended December 31, 2016, and subsequent Forms 10-Q, including
in each case under the heading risk factors, and in the Company’s
other filings with the SEC. The information in this press release
should be read in conjunction with a review of the Company’s
filings with the SEC including the information in the Company’s
Form 10-K for the year ended December 31, 2016, and subsequent
Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171113005603/en/
LabCorpMedia:Pattie Kushner, 336-436-8263orInvestor:Scott
Frommer, 336-436-5076
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024